Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.
作者信息
Daly Timothy, Imbimbo Bruno P
机构信息
UMR 1219 Bordeaux Population Health, Université de Bordeaux & INSERM, Bordeaux, France.
UMR 5164, ImmunoConcept, University of Bordeaux & CNRS, Bordeaux, France.
出版信息
Alzheimers Dement. 2025 Jun;21(6):e70422. doi: 10.1002/alz.70422.
Abstract
摘要
相似文献
1
Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.
Alzheimers Dement. 2025 Jun;21(6):e70422. doi: 10.1002/alz.70422.
2
Response to the letter titled "Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes".
Alzheimers Dement. 2025 Jun;21(6):e70423. doi: 10.1002/alz.70423.
3
homozygotes have less sleep fragmentation in late adulthood.
bioRxiv. 2025 Jun 2:2025.05.30.656615. doi: 10.1101/2025.05.30.656615.
4
Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.
J Alzheimers Dis. 2025 Jun 24:13872877251351329. doi: 10.1177/13872877251351329.
5
Multi-domain interventions for the prevention of dementia and cognitive decline.
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013572. doi: 10.1002/14651858.CD013572.pub2.
6
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
7
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
8
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23.
9
Cerebral hypoperfusion, brain structural integrity, and cognitive impairment in older APOE4 carriers.
Geroscience. 2025 Apr 12. doi: 10.1007/s11357-025-01642-5.
10
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease.
Clin Pharmacokinet. 2025 Mar;64(3):407-424. doi: 10.1007/s40262-025-01482-8. Epub 2025 Feb 5.
本文引用的文献
1
APOE4, Blood Neurodegenerative Biomarkers, and Cognitive Decline in Community-Dwelling Older Adults.
JAMA Netw Open. 2025 May 1;8(5):e258903. doi: 10.1001/jamanetworkopen.2025.8903.
2
The Risk of Alzheimer Disease in APOE4 Homozygotes.
JAMA Neurol. 2025 Apr 14. doi: 10.1001/jamaneurol.2025.0639.
3
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.
JAMA Neurol. 2025 May 1;82(5):450-460. doi: 10.1001/jamaneurol.2025.0360.
4
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.
JAMA Neurol. 2025 May 1;82(5):439-449. doi: 10.1001/jamaneurol.2025.0353.
5
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.
6
Analysis of semaglutide's effect on Alzheimer's disease risk.
Alzheimers Dement. 2025 Feb;21(2):e14462. doi: 10.1002/alz.14462. Epub 2024 Dec 31.
7
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
8
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
9
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
Alzheimers Dement. 2022 Dec;18(12):2687-2698. doi: 10.1002/alz.12624. Epub 2022 Feb 24.
Zotero 插件